KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study.

Vipul Jairath, Geert D'Haens, Bruce E Sands, Simon Travis, María Chaparro, Laurent Peyrin-Biroulet, Min-Hu Chen, Marla Dubinsky, Marc Ferrante, Stefan Schreiber, Kim McGinnis, Aisha Vadhariya, Saskia Appelmans, Zhantao Lin, Guanglei Yu, Marijana Protic, Richard Moses, Subrata Ghosh

Clin Gastroenterol Hepatol 24(2) 463-473.e5

PMID40669578
PMCID-
DOI10.1016/j.cgh.2025.07.003
发表日期2025-07-16
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND & AIMS: Bowel urgency (BU) is an underrecognized and debilitating symptom of Crohn's disease. Mirikizumab, an interleukin-23p19 inhibitor, is efficacious for BU resolution in ulcerative colitis. We evaluated the efficacy of mirikizumab in achieving early BU response and remission among participants with Crohn's disease enrolled in the phase 3 VIVID-1 study. The associations of disease characteristics with baseline BU and BU resolution were explored. METHODS: Adult participants were randomized to receive mirikizumab or placebo. BU was assessed using the Urgency Numeric Rating Scale (NRS) (range 0-10) at baseline, and every 4 weeks. The proportion of participants with baseline Urgency NRS ≥3 and ≥6 who achieved BU clinically meaningful improvement (CMI) (≥3 change in Urgency NRS) and BU remission (Urgency NRS ≤2) was calculated, and associations of BU CMI and BU remission with clinical outcomes were assessed. RESULTS: At baseline, 94.2% of participants had an Urgency NRS score ≥3. BU positively correlated with the Crohn's Disease Activity Index and abdominal pain. Improvement in BU from baseline was significantly greater in mirikizumab-treated participants as early as week 6 and sustained to week 52 vs patients receiving placebo. Participants treated with mirikizumab achieved significantly higher rates of BU CMI and BU remission at weeks 12 and 52 vs placebo. Mirikizumab-treated participants who achieved BU CMI at week 12 had better clinical and endoscopic outcomes at weeks 12 and 52. CONCLUSIONS: Mirikizumab-treated participants achieved significantly higher rates of BU CMI and remission at weeks 12 and 52, which was associated with better short- and longer-term clinical outcomes. CLINICALTRIALS: gov, Number: NCT03926130.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。